Hye Sook Han

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Ivana Yen, Jeeyun Lee, Yong Sang Hong et al. · Nature · 2021 · 133 citations · Full text

Raf Inhibitor Belvarafenib, Melanoma, Pathology +6

TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer

Hye Sook Han, Seongju Jeong, Hyunglae Kim et al. · Cancer Letters · 2020 · 73 citations

Cancer Immunosurveillance, Genitourinary Cancer, Medicine +7

A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients

Yusook Jeong, Hye Sook Han, Hyo Duk Lee et al. · Cancer Research and Treatment · 2016 · 72 citations · Full text

A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial

Yeon Hee Park, Kyung‐Hun Lee, Joohyuk Sohn et al. · International Journal of Cancer · 2018 · 52 citations

MicroRNA‐29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen‐related cell adhesion molecule 6

Hye Sook Han, Seung-Myoung Son, Jieun Yun et al. · FEBS Letters · 2014 · 47 citations · Full text